US 10858323
HDAC inhibitors for the treatment of diabetic peripheral neuropathy
granted A61KA61K31/164A61K31/337
Quick answer
US patent 10858323 (HDAC inhibitors for the treatment of diabetic peripheral neuropathy) held by Regenacy Pharmaceuticals, Inc. expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Regenacy Pharmaceuticals, Inc.
- Grant date
- Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/164, A61K31/337, A61K31/495, A61K31/505